Royal Bank of Canada
VRCA icon

Royal Bank of Canada’s Verrica Pharmaceuticals VRCA Stock Holding History

Royal Bank of Canada’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5K Buy
965
+549
+132% +$3.52K ﹤0.01% 6446
2025
Q4 		$3K Sell
416
-793
-66% -$4.39K ﹤0.01% 6860
2025
Q3 		$5K Buy
1,209
+704
+139% +$4.25K ﹤0.01% 6718
2025
Q2 		$3K Sell
505
-136
-21% -$732 ﹤0.01% 6762
2025
Q1 		$2K Buy
641
+297
+86% +$1.92K ﹤0.01% 6600
2024
Q4 		$2K Sell
344
-2,235
-87% -$24.6K ﹤0.01% 6736
2024
Q3 		$37K Buy
2,579
+2,300
+824% +$104K ﹤0.01% 5843
2024
Q2 		$20K Buy
279
+31
+13% +$2.38K ﹤0.01% 6082
2024
Q1 		$15K Sell
248
-628
-72% -$34.7K ﹤0.01% 6045
2023
Q4 		$64K Sell
876
-78
-8% -$3.21K ﹤0.01% 5878
2023
Q3 		$37K Sell
954
-17
-2% -$864 ﹤0.01% 5936
2023
Q2 		$55K Buy
971
+547
+129% +$33.2K ﹤0.01% 5731
2023
Q1 		$27K Buy
424
+139
+49% +$8.41K ﹤0.01% 5918
2022
Q4 		$8K Buy
285
+1
+0.4% +$27 ﹤0.01% 6623
2022
Q3 		$8K Sell
284
-30,000
-99% -$1.03M ﹤0.01% 6556
2022
Q2 		$581K Buy
30,284
+29,964
+9,364% +$1.51M ﹤0.01% 3955
2022
Q1 		$26K Sell
320
-219
-41% -$18K ﹤0.01% 6471
2021
Q4 		$49K Buy
539
+267
+98% +$30.2K ﹤0.01% 6388
2021
Q3 		$35K Buy
272
+75
+38% +$8.41K ﹤0.01% 6372
2021
Q2 		$22K Sell
197
-11
-5% -$1.33K ﹤0.01% 6527
2021
Q1 		$31K Buy
208
+68
+49% +$9.41K ﹤0.01% 6187
2020
Q4 		$16K Buy
140
+32
+30% +$2.94K ﹤0.01% 6170
2020
Q3 		$8K Sell
108
-2
-2% -$164 ﹤0.01% 6015
2020
Q2 		$12K Sell
110
-37
-25% -$4.28K ﹤0.01% 5778
2020
Q1 		$16K Sell
147
-69
-32% -$9.08K ﹤0.01% 5642
2019
Q4 		$34K Buy
216
+109
+102% +$16.1K ﹤0.01% 5632
2019
Q3 		$16K Hold
107
– – ﹤0.01% 5607
2019
Q2 		$12K Sell
107
-5
-4% -$469 ﹤0.01% 5973
2019
Q1 		$12K Buy
112
+4
+4% +$461 ﹤0.01% 5910
2018
Q4 		$9K Sell
108
-21
-16% -$2.55K ﹤0.01% 5952
2018
Q3 		$21K Buy
129
+2
+2% +$342 ﹤0.01% 5661
2018
Q2 		$25K Buy
+127
New +$24.9K ﹤0.01% 5446

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's VRCA Position: Q1 2026 in Review

Royal Bank of Canada increased its Verrica Pharmaceuticals (VRCA) stake by 132% in Q1 2026, buying an estimated $3.52K and bringing the position to 965 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #6446.

Royal Bank of Canada first reported a position in VRCA in Q2 2018 and has held it in 32 quarters since. The position peaked at $581K in Q2 2022. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Royal Bank of Canada held 965 shares of Verrica Pharmaceuticals worth $5K as of Q1 2026.
  • Royal Bank of Canada bought 549 Verrica Pharmaceuticals shares in Q1 2026, an estimated $3.52K.
  • Verrica Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6446 holding.
  • Royal Bank of Canada first reported a position in Verrica Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
  • Royal Bank of Canada's Verrica Pharmaceuticals position peaked at $581K in Q2 2022.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.